BioMérieux Secures FDA Clearance for Enhanced Gastroenteritis Test

bioMérieux, a prominent player in in vitro diagnostics, has received FDA clearance for the BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid. This molecular test targets 11 common pathogens behind gastroenteritis, offering results within an hour from a single sample.

Acute gastroenteritis, marked by diarrhea and vomiting, poses serious health risks, especially for vulnerable groups. Traditional diagnostics often fall short, leading to ineffective treatment decisions. The new panel aims to address these issues by enhancing diagnostic precision and efficiency.

Compatible with BIOFIRE® FILMARRAY® platforms, the panel requires minimal setup time and offers a swift diagnostic alternative. It supplements bioMérieux's existing GI panels, empowering clinicians with faster, more informed decision-making capabilities.